What the cholera mortality curve says about kit readiness
The value of a pre-positioned kit is best understood through the disease it is most often built for. Severe cholera left untreated kills somewhere between 30 and 50 percent of those it strikes; with prompt rehydration the case-fatality rate falls below one percent. But that collapse in mortality is entirely time-dependent — the rehydration has to begin in the first hours of severe dehydration, not in the second week of a procurement cycle. A standardised kit exists precisely to buy those hours: it converts a response that would otherwise wait weeks for a bespoke order into one that can begin treating on day zero. The kit is, in effect, the delivery mechanism for the under-one-percent figure.
The discipline the kit demands is honesty about its limits. MSF's own cholera-kit guidance states plainly that the kit does not contain everything needed to run a treatment centre — tents, additional sheeting, beds and chairs, and staff clothing are excluded or under-supplied by design — so a supplementary order must run alongside the kit release. The 2024 global oral-cholera-vaccine shortage, in which requests for 8.4 million doses could only be partly met and a deficit of tens of millions of doses persisted, is a reminder that even the most standardised supply chains run dry under surge. Pre-positioning, shelf-life rotation, and a planned second and third kit are not refinements; they are what keeps the mortality curve flat when the first kit is opened.